PL3326645T3 - Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM - Google Patents

Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM

Info

Publication number
PL3326645T3
PL3326645T3 PL17192860T PL17192860T PL3326645T3 PL 3326645 T3 PL3326645 T3 PL 3326645T3 PL 17192860 T PL17192860 T PL 17192860T PL 17192860 T PL17192860 T PL 17192860T PL 3326645 T3 PL3326645 T3 PL 3326645T3
Authority
PL
Poland
Prior art keywords
differences
svcam
alpha
methods
correlating
Prior art date
Application number
PL17192860T
Other languages
English (en)
Inventor
Alissa A. Chackerian
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of PL3326645T3 publication Critical patent/PL3326645T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL17192860T 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM PL3326645T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40635810P 2010-10-25 2010-10-25
US40636510P 2010-10-25 2010-10-25
PCT/US2011/057519 WO2012061074A1 (en) 2010-10-25 2011-10-24 METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
EP17192860.9A EP3326645B1 (en) 2010-10-25 2011-10-24 Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
EP11838481.7A EP2632492B1 (en) 2010-10-25 2011-10-24 METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS

Publications (1)

Publication Number Publication Date
PL3326645T3 true PL3326645T3 (pl) 2020-09-21

Family

ID=46024768

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17192860T PL3326645T3 (pl) 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach sVCAM i/lub sMAdCAM
PL20162844.3T PL3722808T3 (pl) 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20162844.3T PL3722808T3 (pl) 2010-10-25 2011-10-24 Sposoby określania różnic w aktywności integryn alfa-4 przez korelowanie różnic w poziomach svcam i/lub smadcam

Country Status (18)

Country Link
US (3) US20130337470A1 (pl)
EP (3) EP3722808B1 (pl)
JP (2) JP5847188B2 (pl)
AU (4) AU2011323820A1 (pl)
CA (1) CA2816016A1 (pl)
CY (1) CY1123060T1 (pl)
DK (2) DK3722808T3 (pl)
ES (3) ES2997080T3 (pl)
FI (1) FI3722808T3 (pl)
HR (2) HRP20241666T1 (pl)
HU (2) HUE050713T2 (pl)
LT (2) LT3326645T (pl)
PL (2) PL3326645T3 (pl)
PT (2) PT3722808T (pl)
RS (2) RS60565B1 (pl)
SI (2) SI3722808T1 (pl)
SM (2) SMT202400498T1 (pl)
WO (1) WO2012061074A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2997080T3 (en) 2010-10-25 2025-02-14 Biogen Ma Inc Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
CA2969326A1 (en) * 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5338689A (en) 1987-08-24 1994-08-16 Stiftung Fur Diagnostische Forschung Method and card for detecting antigens and/or antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5260210A (en) 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
BE1008817A6 (fr) 1994-10-28 1996-08-06 Univ Bruxelles Procede d'obtention d'adn bicatenaire membranaire humain, produit obtenu par ce procede et trousse de diagnostic le contenant.
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647382A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
US5965356A (en) 1997-01-31 1999-10-12 University Of Maryland, Baltimore Herpes simplex virus type specific seroassay
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999058573A1 (en) * 1998-05-13 1999-11-18 Genentech, Inc. Diagnosis and treatment of hepatic disorders
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6756378B2 (en) 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
PL357109A1 (pl) 1999-12-28 2004-07-12 Pfizer Products Inc. Niepeptydylowe inhibitory zależnego od VLA-4 wiązania komórek, użyteczne w leczeniu chorób zapalnych, autoimmunologicznych i chorób układu oddechowego
ATE448306T1 (de) * 2000-09-01 2009-11-15 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
US7576101B2 (en) 2003-01-24 2009-08-18 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
EP2394652A3 (en) 2004-02-06 2012-10-24 Elan Pharmaceuticals Inc. Methods and compositions for treating tumors and metastatic disease
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
CA2561164A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and their use
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
WO2006096461A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
SI2645106T2 (sl) * 2005-04-04 2025-05-30 Biogen Ma Inc. Metode za ocenjevanje imunskega odziva na terapevtsko sredstvo
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
AU2007224228B2 (en) 2006-03-03 2013-09-19 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
CA2708262A1 (en) 2007-12-07 2009-06-18 Elan Pharmaceuticals, Inc. Methods and compositions for treating liquid tumors
WO2009140684A2 (en) * 2008-05-16 2009-11-19 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
WO2009141786A2 (en) 2008-05-21 2009-11-26 Piramal Life Sciences Limited Anti-inflammatory compounds
WO2010053316A2 (en) 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
NZ577731A (en) * 2009-06-16 2010-08-27 Innate Therapeutics Ltd Compositions and methods for treatment of multiple sclerosis
JP2013525435A (ja) * 2010-04-30 2013-06-20 エラン ファーマシューティカルズ，インコーポレイテッド 選択的インテグリン阻害剤
ES2997080T3 (en) 2010-10-25 2025-02-14 Biogen Ma Inc Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels

Also Published As

Publication number Publication date
LT3722808T (lt) 2024-12-27
EP3326645A1 (en) 2018-05-30
DK3326645T3 (da) 2020-06-15
AU2017201658A1 (en) 2017-03-30
US20160291035A1 (en) 2016-10-06
PT3722808T (pt) 2024-12-09
AU2019204089A1 (en) 2019-07-04
US11079393B2 (en) 2021-08-03
PT3326645T (pt) 2020-06-23
WO2012061074A1 (en) 2012-05-10
HUE069385T2 (hu) 2025-03-28
US20220206012A1 (en) 2022-06-30
ES2997080T3 (en) 2025-02-14
EP2632492B1 (en) 2017-10-04
HRP20200920T1 (hr) 2020-10-30
US20130337470A1 (en) 2013-12-19
JP2014500950A (ja) 2014-01-16
DK3722808T3 (da) 2024-12-09
SI3326645T1 (sl) 2020-09-30
RS60565B1 (sr) 2020-08-31
RS66261B1 (sr) 2024-12-31
AU2017201658B2 (en) 2019-03-21
SMT202400498T1 (it) 2025-01-14
ES2654820T3 (es) 2018-02-15
EP3722808B1 (en) 2024-09-11
PL3722808T3 (pl) 2025-02-03
LT3326645T (lt) 2020-08-10
FI3722808T3 (fi) 2024-12-10
CA2816016A1 (en) 2012-05-10
HUE050713T2 (hu) 2020-12-28
HK1256157A1 (en) 2019-09-13
AU2011323820A1 (en) 2013-05-23
EP2632492A4 (en) 2014-04-02
EP3326645B1 (en) 2020-03-18
SMT202000380T1 (it) 2020-09-10
ES2800066T3 (es) 2020-12-23
AU2021212059A1 (en) 2021-08-26
JP2015215363A (ja) 2015-12-03
HRP20241666T1 (hr) 2025-02-14
EP2632492A1 (en) 2013-09-04
SI3722808T1 (sl) 2025-02-28
AU2021212059B2 (en) 2025-02-27
EP3722808A1 (en) 2020-10-14
JP5847188B2 (ja) 2016-01-20
CY1123060T1 (el) 2021-10-29

Similar Documents

Publication Publication Date Title
SG11201401913YA (en) Systems and methods for biological analysis
GB201420407D0 (en) Multi-cue object detection and analysis
IL227579A0 (en) Systems and methods for maximizing the use of samples
EP2629051A4 (en) THICKNESS MEASURING DEVICE AND MEASURING METHOD THEREFOR
SG11201401956XA (en) Undifferentiated cell detection method and complex carbohydrate detection method
PT2663864T (pt) Método de avaliação de imunodiversidade e seu uso
EP2788794A4 (en) PERMEABILITY PREDICTION SYSTEMS AND METHODS INVOLVING QUADRATIC DISCRIMINANT ANALYSIS
EP2845003A4 (en) IMPROVED ANALYTIC METHOD AND SYSTEM
EP2705135A4 (en) SYSTEMS AND METHODS FOR ANALYZING BASOPHILES
IL222752A0 (en) Acoustic methods and systems for detecting terahertz radioation
ZA201208522B (en) Methods for measuring enzyme activity useful in determining cell viability in non-purified sapmles
EP2553115A4 (en) METHODS OF CULTURE AND ANALYSIS OF CELLS
SG11201401911XA (en) Systems and methods for biological analysis
EP2612256A4 (en) IMPLEMENTATION OF »WHAT-IF-ANALYSIS
EP2762557A4 (en) CELL IDENTIFICATION DEVICE AND PROGRAM
EP2726813A4 (en) SURFACE MEASURING SYSTEM AND METHOD
EP2640407A4 (en) PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN
EP2693195A4 (en) SPR SENSOR CELL, AND SPR SENSOR
EP2576809A4 (en) MEASURE A YEAST CONCENTRATION AND LIFE CAPABILITY
GB201207583D0 (en) Electrochemical detection method and related aspects
SI3722808T1 (sl) Metode za determinacijo razlik v alfa- 4 integrin aktivnosti s korelacijo razlik v svcam in/ali smadcam nivojih
EP2757363A4 (en) PLASMON SURFACE RESONANCE SENSOR CELL (SPR) AND SPR SENSOR
EP2725343A4 (en) SPR SENSOR CELL AND SPR SENSOR
PL2710950T3 (pl) Sposób oraz system pomiaru rozpraszania wewnątrzgałkowego
EP2693196A4 (en) SPR SENSOR CELL AND SPR SENSOR